Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis-Reference-Cited by-同舟云学术

Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis

Published:2020-10-08 Issue:52 Volume:5 Page:
ISSN:2470-9468
Container-title:Science Immunology
language:en
Short-container-title:Sci. Immunol.

Author:

Lee James C.¹²³⁴^ORCID,Mehdizadeh Sadaf²³^ORCID,Smith Jennifer²³^ORCID,Young Arabella²³⁵^ORCID,Mufazalov Ilgiz A.²³^ORCID,Mowery Cody T.³⁶^ORCID,Daud Adil¹⁴⁷⁸^ORCID,Bluestone Jeffrey A.²³⁴⁷⁸^ORCID

Affiliation:

1. Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA 94143, USA.

2. Sean N. Parker Autoimmune Research Laboratory, University of California, San Francisco, San Francisco, CA 94143, USA.

3. Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA.

4. Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.

5. QIMR Berghofer Medical Research Institute, Herston, Queensland 4006, Australia.

6. Medical Scientist Training Program, University of California, San Francisco, San Francisco, CA 94143, USA.

7. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA.

8. Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.

Abstract

Liver metastasis suppresses systemic tumor-specific immunity and contributes to the resistance to checkpoint immunotherapy.

Funder

National Institutes of Health

A.P. Giannini Foundation

Parker Institute for Cancer Immunotherapy

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine,Immunology

Reference71 articles.

1. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

2. Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD-1 therapy;Pires da Silva I.;Cancer,2020

3. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC);Schmid S.;Cancer Immunol. Immunother.,2018

4. Sites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO);Bilen M. A.;BMC Cancer,2019

5. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer;Sasaki A.;Gastric Cancer,2019

Cited by 181 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance;Drug Resistance Updates;2024-11

2. Immune modulation of the liver metastatic colorectal cancer microenvironment via the oral CAPOX-mediated cGAS-STING pathway;Biomaterials;2024-10

3. Infiltrating treg reprogramming in the tumor immune microenvironment and its optimization for immunotherapy;Biomarker Research;2024-09-04

4. Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment;Frontiers in Immunology;2024-09-03

5. Remodeling the hepatic immune microenvironment and demolishing T cell traps to enhance immunotherapy efficacy in liver metastasis;Journal of Controlled Release;2024-09